Maze Therapeutics (NASDAQ:MAZE) Hits New 12-Month High – Should You Buy?

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $51.36 and last traded at $51.06, with a volume of 1289453 shares trading hands. The stock had previously closed at $45.06.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on MAZE shares. Guggenheim upped their price target on Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Mizuho assumed coverage on shares of Maze Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $97.00 target price on the stock. Wells Fargo & Company initiated coverage on shares of Maze Therapeutics in a research note on Thursday, December 4th. They issued an “overweight” rating and a $55.00 target price for the company. Lifesci Capital raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Maze Therapeutics in a research note on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $54.63.

Maze Therapeutics Stock Performance

The firm has a fifty day simple moving average of $44.61 and a 200-day simple moving average of $35.34. The company has a market capitalization of $2.49 billion, a PE ratio of -2.48 and a beta of 4.47.

Insider Transactions at Maze Therapeutics

In related news, CMO Harold Bernstein sold 30,000 shares of Maze Therapeutics stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $50.45, for a total value of $1,513,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Amy Bachrodt sold 5,000 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $46.04, for a total transaction of $230,200.00. Following the completion of the sale, the senior vice president directly owned 12,965 shares in the company, valued at $596,908.60. This represents a 27.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 230,000 shares of company stock valued at $9,768,292.

Hedge Funds Weigh In On Maze Therapeutics

Several large investors have recently modified their holdings of MAZE. Frazier Life Sciences Management L.P. grew its stake in Maze Therapeutics by 10.6% in the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after purchasing an additional 438,274 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Maze Therapeutics by 318.0% during the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after buying an additional 2,390,713 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Maze Therapeutics by 27.1% in the 4th quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock worth $70,307,000 after acquiring an additional 362,060 shares in the last quarter. Woodline Partners LP grew its position in shares of Maze Therapeutics by 10.0% in the 3rd quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock worth $26,843,000 after acquiring an additional 94,529 shares in the last quarter. Finally, Marshall Wace LLP increased its holdings in shares of Maze Therapeutics by 9.0% in the 4th quarter. Marshall Wace LLP now owns 847,472 shares of the company’s stock valued at $35,111,000 after acquiring an additional 69,771 shares during the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.